Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Crossmint Secures Payment Institution and MiCA Authorization, Completing a Full-Stack EU Regulatory Stack for Stablecoin Payments3.7.2026 21:00:00 CEST | Press release
With Authorization as a Crypto-Asset Service Provider Under MiCA and Payment Institution Under PSD2, Crossmint Now Operates Under Both of the EU's Core Frameworks for Stablecoin Infrastructure, Giving Enterprise Fintechs One Regulated Provider to Hold Stablecoins and Move Them as Payments MADRID, ES / ACCESS Newswire / July 3, 2026 / Crossmint has been authorized as a Payment Institution (PI) by the Bank of Spain under the EU's Payment Services Directive (PSD2). Earlier this year, Crossmint received MiCA class 2 authorization from Spain's CNMV, establishing complete authorization to operate as a crypto-asset service provider across the EU. After completing the required conditions, Crossmint has now successfully been fully registered as a CASP with CNMV, which allows passporting across all 27 EU member states. PSD2 authorization is the natural expansion of that compliance footprint, enabling stablecoins to be used as a means of payment under EU payments law. "Crossmint's mission is to b
Polaris Renewable Energy Announces Q2 2026 Investor Call Details3.7.2026 19:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 3, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2026 Earnings Results on Thursday, July 30th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 503447 or URL: https://www.webcaster5.com/Webcast/Page/2773/53517 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 53517 International (toll-free): 1 919-882-2331, Passcode: 53517 Encore Replay Expiration Date: August 13, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing a
GoodData.AI Recognized in 2026 Gartner(R) Magic Quadrant(TM) for Analytics and BI Platforms2.7.2026 14:05:00 CEST | Press release
GoodData.AI positioned as a Visionary by Gartner® for completeness of vision and ability to execute. SAN FRANCISCO, CA / ACCESS Newswire / July 2, 2026 / GoodData.AI, the AI-native analytics platform, today announced its recognition as a Visionary in the 2026 Gartner® Magic Quadrant™ for Analytics and Business Intelligence Platforms. For GoodData.AI, this recognition marks a significant milestone, reflecting its journey of recognition from a Niche Player to a Visionary - a testament to the company's continued investment in its composable, AI-native analytics architecture and the growing enterprise demand for developer-centric, embedded analytics at scale. At the heart of GoodData.AI's platform is a headless semantic layer that serves as the governed foundation for business intelligence, data science, AI agents, and embedded application experiences. The platform's analytics-as-code approach enables development teams to build, automate and govern analytics like any other software compone
U.S. Polo Assn. Celebrates 250 Years of American Spirit and Collaborates with ESPN on 'Polo in America' Broadcast Special2.7.2026 13:00:00 CEST | Press release
Global sports brand commemorates enduring connection between sport and American culture WEST PALM BEACH, FL / ACCESS Newswire / July 2, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), proudly marks America's 250th Anniversary with a celebration of the nation's enduring spirit - one rooted in sport, heritage, and a distinctly American sense of style. To highlight the connection between U.S. Polo Assn. and the sport of polo, the brand is collaborating with ESPN on a 30-minute broadcast special, 'Breakaway: Polo in America.' The award-winning Breakaway Series will produce a special episode to give audiences an inside look at the long history and significant impact the sport of polo has had on America over the past century. This episode will broadcast globally on ESPN and on Global Polo's YouTube. Founded in 1890, the USPA is one of the oldest national governing bodies for sport in the United States, and U.S. Polo Assn. carries that legacy f
The Inaugural Michelin Guide New Zealand Reveals 1 Two Michelin Stars, 14 One Michelin Star And 35 Bib Gourmands1.7.2026 23:40:00 CEST | Press release
AUCKLAND, NZ / ACCESS Newswire / July 1, 2026 / The inaugural MICHELIN Guide New Zealand 2026 has recognised 110 restaurants across Auckland, Wellington, Christchurch and Queenstown, celebrating exceptional quality, creativity and a strong sense of place. After months of anonymous inspections, the MICHELIN Guide has awarded one restaurant in Queenstown, Essence, Two MICHELIN Stars. Fourteen restaurants have received One MICHELIN Star, 35 have been recognised with a Bib Gourmand for offering good food at great value, and a further 60 are included in the official MICHELIN Guide selection. Gwendal Poullennec, International Director of the MICHELIN Guide, said: "It is rare to award such a quantity of Stars in a country's inaugural launch, New Zealand's performance has been genuinely impressive. The destination presents more than a selection of outstanding restaurants; to our Inspectors, it revealed a contemporary culinary map shaped by unique terroir and a food culture in quiet harmony wit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom